[go: up one dir, main page]

EP0548125A1 - Substituted 6,7-dihydroimidazo(1,5,4-ef)(1,5)benzodiazepin-6-ones, their preparation and pharmaceutical compositions - Google Patents

Substituted 6,7-dihydroimidazo(1,5,4-ef)(1,5)benzodiazepin-6-ones, their preparation and pharmaceutical compositions

Info

Publication number
EP0548125A1
EP0548125A1 EP91915634A EP91915634A EP0548125A1 EP 0548125 A1 EP0548125 A1 EP 0548125A1 EP 91915634 A EP91915634 A EP 91915634A EP 91915634 A EP91915634 A EP 91915634A EP 0548125 A1 EP0548125 A1 EP 0548125A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
formula
compound
integer
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91915634A
Other languages
German (de)
French (fr)
Inventor
Kelvin Pfizer Central Research Cooper
Michael Jonathan Pfizer Central Research Fray
John Pfizer Central Research Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd Great Britain
Pfizer Inc
Original Assignee
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Ltd Great Britain, Pfizer Corp SRL, Pfizer Inc filed Critical Pfizer Corp Belgium
Publication of EP0548125A1 publication Critical patent/EP0548125A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • This invention relates to diazepine derivatives which are potent, orally active antagonists of platelet activating factor and as such have clinical utility for treating allergic and inflammatory conditions such as asthma and arthritis respectively.
  • Platelet activating factor (PAF, 1-0-alkyl-2-acetyl-sn- glyceryl-3-phosphorylcholine) is an ether phospholipid whose structure was first elucidated in 1979. It is produced by, released from and interacts with many pro-inflammatory cells, platelets and the kidney. In addition to potent platelet
  • PAF aggregating activity
  • PAF exhibits a wide spectrum of biological activities elicited either directly or via the release of other powerful mediators such as thrcmb ⁇ xane A 2 or the leukotrienes.
  • PAF stimulates the movement and aggregation of neutrqphils and the release therefrom of tissue-damaging enzymes and oxygen radicals. These activities contribute to actions of PAF in vivo consistent with it playing a significant role in inflammatory and allergic responses.
  • intradermal PAF has been shown to induce an inflammatory response, with associated pain
  • PAF has been implicated as being involved in a number of other medical conditions.
  • circulatory shock which is characterised by systemic hypotension, pulmonary hypertension and increased lung vascular permeability
  • the symptoms can be mimicked by infusion of PAF.
  • This coupled with evidence shewing that circulating PAF levels are increased by endotoxin infusion indicate that PAF is a prime mediator in certain forms of shock.
  • Intravenous infusion of PAF at doses of 20-200 pmol kg -1 min -1 into rats results in the formation of extensive haemorrhagic erosions in the gastric mucosa and thus PAF is the most potent gastric ulcerogen yet described whose
  • Psoriasis is an inflammatory and
  • PAF proliferative disease characterised by skin lesions.
  • PAF is pro-inflammatory and has been isolated from lesi ⁇ ned scale of psoriatic patients indicating PAF has a role in the disease of psoriasis.
  • increasing evidence supports a potential pathophysiological role for PAF in cardiovascular disease.
  • shew PAF is released during atrial pacing and, in pigs, intcracoronary injection of PAF induces a prolonged decrease in coronary flow while in guinea pig hearts it induces regional shunting and ischaeraia.
  • PAF has also been shewn to initiate thrombus formation in a mesentenic artery preparation both when administered exogenously and when released endogenously. More recently PAF has been shewn to play a role in brain ischaemia induced in animal models of stroke.
  • European Patent Application No. 0258033 we disclose a series of 2-substituted 1,4-dihydropyridine derivatives as PAF antagonists.
  • European Patent Application 0310386 we disclose a further series of dihydropyridine PAF antagonists in which the 2-position substituent may be a 2-methyl-imidazo[4,5-c]- pyrid-1-phenyl group.
  • R 1 is either H or C 1 -C 4 alkyl optionally substituted by a substituent selected from phenyl, halophenyl, pyridyl, (C 1 -C 4 alkoxy) carbonyl and di-(C 1 -C 4 alkyl) amino, or C 2 -C 4 alkyl substituted by hydroxyl or by one or two C 1 -C 4 alkoxy groups or is (CH 2 ) n CONR 7 R 8 where n is an integer from 1 to 4 and R 7 and R 8 are each independently H or C 1 -C 4 alkyl, and R 2 is selected from H, OH and
  • R 3 is selected from halo or C 1 -C 4 alkyl;
  • R 4 is methyl; p is 0-3 and m is 0-3; and their
  • R 1 are H, CH 3 and ethoxycarbonylmethyl.
  • R 2 may be selected from H, OH and CH 3 .
  • Particularly preferred compounds are 7-methyl-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-
  • Such compounds and their salts may exist as one tautomer or as a mixture of tautomers, which may generally be separated by physical means such as fractional crystallisation or
  • the invention includes all tautcmers whether separated or not.
  • R 1 , R 2 or R 3 comprises a branched alkyl or alkoxy group having 4 carbon atoms
  • the compound may contain a chiral centre and exist as a pair of isomers which may be separated by conventional means.
  • the invention includes all such enantiomers, whether separated or not.
  • the pharmaceutically acceptable salts of the compounds of formula (I) are those formed from acids which form non-toxic addition salts, for example the hydrcchloride, hydrobromide, sulphate or bisulphate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, tartrate, methane-sulphonate and dimethane-sulphonate,
  • R 1 is H and R 2 is H or C 1 -C 4 alkyl
  • the compounds of formula (I) may be made by the following method.
  • R 4 reacts with an orthoester of the appropriate carboxylic acid in the presence of that acid and compound (I) may be isolated by conventional means.
  • the compound (I) in which R 2 is OH may be made from compound
  • substituted alkyl may be prepared from the corresponding compounds in which R 1 is H by reaction of the latter with compound R 1 -X when
  • X is chloro, bromo or iodo.
  • the reaction is generally conducted in the presence of a base such as sodium hydride.
  • the activity of the compounds of the invention is shewn by their ability to inhibit the platelet aggregating activity of PAF in vitro. Testing is performed as follows:
  • Elood samples are taken from either rabbit or man into 0.1 vol disodium ethylenediamine tetraacetic acid buffer and the samples centrifuged for 15 minutes to obtain platelet rich plasma. The plasma is further centrifuged to give a platelet pellet which is washed with a buffer solution (4 nM KH 2 PO 4 , 6mM Na 2 HPO 4 , 100 mM NaCl, 0.1% glucose and 0.1% bovine serum albumin, pH 7.25) and finally resuspended in buffer solution to a concentration of
  • the activity of the compounds of formula (I) is also demonstrated in vivo by their ability to protect mice from the lethal effect of an injection of PAF.
  • a mixture of PAF (50 ⁇ g/kg) and DL-propranolol (5 mg/kg) in 0.9% w/v sodium chloride is injected (0.2 ml) via a tail vein into mice.
  • the compounds under test are either injected into the tail vein immediately prior to the PAF/propranolol injection or administered orally by gavage two hours earlier.
  • the compounds are tested at several doses in groups of 5 mice and the dose which reduces mortality to 50% is recorded as the PD 50 value.
  • the compounds of the formula (I) will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of
  • compositions for example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for exanple, enough salts or glucose to make the solution isotonic with blood.
  • oral dosages of the compounds will generally be in the range of from 2-1000 mg daily for an average adult patient (70 kg).
  • individual tablets or capsules contain from 1 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier.
  • administration would typically be within the range 1 to 10 mg per single dose as required.
  • inhalation via a nebuliser or aerosol may be the preferred route of drug administration.
  • Dose levels by this route would be within the range 0.1 to 50 mg per single dose as required.
  • physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • the invention provides a
  • composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
  • the invention also includes a compound of the formula (I) or a pharmaceutically acceptable salt thereof, for use in medicine, in particular in the treatment of allergic and
  • reaction mixture On cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate such that the aqueous phase had pH8.
  • the organic extract was washed with water, dried over magnesium sulphate and the drying agent filtered off.
  • Pre-adsorption silica Karlgel 60, 70-230 mesh, 1g was added to the filtrate which was concentrated to dryness under reduced pressure. The residue was purified by flash
  • This compound was prepared by the method of Example 1 substituting teiethylorthoacetate and acetic acid for
  • Example 1 (0.51g, 1.3mmol) in anhydrous dimethylformamide (10ml) under nitrogen. After being stirred under reflux for 1 hour, the reaction inixture was cooled to room temperature, whereupon ethyl bromoacetate (0.166ml, 1.5mmol) was added and the solution stirred for an additional 36 hours at room temperature. The dimethylformamide was evaporated off under reduced pressure. The residue was diluted with water, hydrochloric acid (2M) added to give pH1, followed by sodium hydrogen carbonate to give pH8 and product extracted with ethyl acetate. The organic extract was washed three times with water, dried over magnesium sulphate and the drying agent filtered off. Pre-adsorption silica (Kieselgel 60,70-230 mesh, 2g) was added to the filtrate which was evaporated to dryness under reduced pressure.
  • ethyl bromoacetate (0.166ml, 1.5mmol
  • Example 4 The procedure of Example 4 was followed, using methyl iodide instead of ethyl bromoacetate, to yield the title compound, (30mg, 13%).
  • Step (b) belcw, m.p. 200°C (broad).
  • Ethyl 4'-(2-mtethylimidazo[4,5-c]-pyrid-1-yl)benzoylacetate may be prepared as described in European Patent Application No. 0310386A.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Antagonistes de facteurs d'activation plaquettaire de formule (I), où R1 représente H ou alkyle C1-C4 éventuellement substitué par un susbtituant choisi à partir de phényle, halophényle, pyridyle, carbonyle (alcoxy C1-C4) et di-(alkyle C1-C4) amino, ou représente alkyle C2-C4 substitué par un hydroxyle ou par un ou deux groupes alcoxy ou représente (CH2)nCONR7R8 où n est un nombre entier compris entre 1 et 4 et R7 et R8 représentent chacun indépendamment H ou alkyle C1-C4, R2 est choisi à partir de H, OH, et alkyle C1-C4, R3 est choisi à partir de halo et alkyle C1-C4, R4 représente méthyle et p est un nombre entier compris entre 0 et 3 et m est un nombre entier compris ente 0 et 3; ou un sel pharmaceutiquement acceptable de ces composés.Antagonists of platelet activating factors of formula (I), in which R1 represents H or C1-C4 alkyl optionally substituted by a substance chosen from phenyl, halophenyl, pyridyl, carbonyl (C1-C4 alkoxy) and di- (C1 alkyl -C4) amino, or represents C2-C4 alkyl substituted by a hydroxyl or by one or two alkoxy groups or represents (CH2) nCONR7R8 where n is an integer between 1 and 4 and R7 and R8 each independently represent H or C1 alkyl -C4, R2 is chosen from H, OH, and C1-C4 alkyl, R3 is chosen from halo and C1-C4 alkyl, R4 represents methyl and p is an integer between 0 and 3 and m is a whole number between 0 and 3; or a pharmaceutically acceptable salt of these compounds.

Description

SUBSTITUTED 6,7-DIHYDROIMIDAZO(1,5,4-EF)(1,5)
BENZ0DIAZEPIN-6-ONES, THEIR PREPARATION AND
PHARMACEUTICAL COMPOSITIONS
This invention relates to diazepine derivatives which are potent, orally active antagonists of platelet activating factor and as such have clinical utility for treating allergic and inflammatory conditions such as asthma and arthritis respectively.
Platelet activating factor (PAF, 1-0-alkyl-2-acetyl-sn- glyceryl-3-phosphorylcholine) is an ether phospholipid whose structure was first elucidated in 1979. It is produced by, released from and interacts with many pro-inflammatory cells, platelets and the kidney. In addition to potent platelet
aggregating activity, PAF exhibits a wide spectrum of biological activities elicited either directly or via the release of other powerful mediators such as thrcmbαxane A2 or the leukotrienes. In vitro, PAF stimulates the movement and aggregation of neutrqphils and the release therefrom of tissue-damaging enzymes and oxygen radicals. These activities contribute to actions of PAF in vivo consistent with it playing a significant role in inflammatory and allergic responses. Thus, intradermal PAF has been shown to induce an inflammatory response, with associated pain,
accumulation of inflammatory cells and increased vascular
permeability, comparable with the allergic skin reaction following exposure to allergen. Similarly, both the acute broncho- constriction and chronic inflammatory reactions elicited by allergens in asthma can be mimicked by intratracheal administration of PAF. Accordingly agents which antagonise the actions of PAF and, consequently also prevent mediator release by PAF, will have clinical utility in the treatment of a variety of allergic and inflammatory conditions such as asthma and arthritis, respectively.
In addition to the above, PAF has been implicated as being involved in a number of other medical conditions, Thus in circulatory shock, which is characterised by systemic hypotension, pulmonary hypertension and increased lung vascular permeability, the symptoms can be mimicked by infusion of PAF. This coupled with evidence shewing that circulating PAF levels are increased by endotoxin infusion indicate that PAF is a prime mediator in certain forms of shock. Intravenous infusion of PAF at doses of 20-200 pmol kg-1 min-1 into rats results in the formation of extensive haemorrhagic erosions in the gastric mucosa and thus PAF is the most potent gastric ulcerogen yet described whose
endogenous release may underlie or contribute to certain forms of gastric ulceration. Psoriasis is an inflammatory and
proliferative disease characterised by skin lesions. PAF is pro-inflammatory and has been isolated from lesiαned scale of psoriatic patients indicating PAF has a role in the disease of psoriasis. And finally, increasing evidence supports a potential pathophysiological role for PAF in cardiovascular disease. Thus recent studies in angina patients shew PAF is released during atrial pacing and, in pigs, intcracoronary injection of PAF induces a prolonged decrease in coronary flow while in guinea pig hearts it induces regional shunting and ischaeraia. PAF has also been shewn to initiate thrombus formation in a mesentenic artery preparation both when administered exogenously and when released endogenously. More recently PAF has been shewn to play a role in brain ischaemia induced in animal models of stroke.
Thus compounds of the invention, by virtue of their ability to antagonise the actions of PAF, could well be of value in the treatment of any of the above conditions.
In European Patent Application No. 0258033 we disclose a series of 2-substituted 1,4-dihydropyridine derivatives as PAF antagonists. In European Patent Application 0310386 we disclose a further series of dihydropyridine PAF antagonists in which the 2-position substituent may be a 2-methyl-imidazo[4,5-c]- pyrid-1-phenyl group.
According to the present invention, there are provided compounds of formula (I):
wherein R1 is either H or C1-C4 alkyl optionally substituted by a substituent selected from phenyl, halophenyl, pyridyl, (C1-C4 alkoxy) carbonyl and di-(C1-C4 alkyl) amino, or C2-C4 alkyl substituted by hydroxyl or by one or two C1-C4 alkoxy groups or is (CH2)nCONR7R8 where n is an integer from 1 to 4 and R7 and R8 are each independently H or C1-C4 alkyl, and R2 is selected from H, OH and
C1-C4 alkyl; R3 is selected from halo or C1-C4 alkyl; R4 is methyl; p is 0-3 and m is 0-3; and their
pharmaceutically acceptable salts.
Examples of R1 are H, CH3 and ethoxycarbonylmethyl. R2 may be selected from H, OH and CH3. Particularly preferred compounds are 7-methyl-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-
6,7-dihydroimidazo[1,5,4-ef][1,5]benzodiazepin-6-one, in which R1 is CH3 and R2 is H and m and p are 0; and 4-[4-(2-methylimidazo-
[4,5-c]pyrid-1-yl)phenyl]-7-ethoxycarborylmethyl-6,7- dihydroxmidazo[1,5,4-ef][1,5] benzodιazepxn-6-one, in which R1 is ethoxycarbonyl methyl and R2 is H and m and p are 0.
When R2 is OH formula (I) may alternatively be written as formula (la), these forms of the compound being tautomeric.
Such compounds and their salts may exist as one tautomer or as a mixture of tautomers, which may generally be separated by physical means such as fractional crystallisation or
chromatography. The invention includes all tautcmers whether separated or not.
When at least one of R1, R2 or R3 comprises a branched alkyl or alkoxy group having 4 carbon atoms the compound may contain a chiral centre and exist as a pair of isomers which may be separated by conventional means. The invention includes all such enantiomers, whether separated or not.
The pharmaceutically acceptable salts of the compounds of formula (I) are those formed from acids which form non-toxic addition salts, for example the hydrcchloride, hydrobromide, sulphate or bisulphate, phosphate or acid phosphate, acetate, citrate, fumarate, gluconate, lactate, maleate, succinate, tartrate, methane-sulphonate and dimethane-sulphonate,
benzenesulphonate and p-toluenesulphonate.
When R1 is H and R2 is H or C1-C4 alkyl the compounds of formula (I) may be made by the following method.
In this method 6-amino-4-[4-(2-methylimidazo[4,5-c]pyrid-
1-yl)phenyl][1,5]benzodiazepin-4-one (see Preparation), or the derivative thereof containing the appropriate substituents R3 and
R4 (compound II) reacts with an orthoester of the appropriate carboxylic acid in the presence of that acid and compound (I) may be isolated by conventional means.
The compound (I) in which R2 is OH may be made from compound
(II) by reaction of the latter with trichlorcroethyl chloroformate in 1,2-dichloroethane as a solvent.
Compounds of formula (I) in which R1 is optionally
substituted alkyl may be prepared from the corresponding compounds in which R1 is H by reaction of the latter with compound R1-X when
X is chloro, bromo or iodo. The reaction is generally conducted in the presence of a base such as sodium hydride.
The activity of the compounds of the invention is shewn by their ability to inhibit the platelet aggregating activity of PAF in vitro. Testing is performed as follows:
Elood samples are taken from either rabbit or man into 0.1 vol disodium ethylenediamine tetraacetic acid buffer and the samples centrifuged for 15 minutes to obtain platelet rich plasma. The plasma is further centrifuged to give a platelet pellet which is washed with a buffer solution (4 nM KH2PO4, 6mM Na2HPO4, 100 mM NaCl, 0.1% glucose and 0.1% bovine serum albumin, pH 7.25) and finally resuspended in buffer solution to a concentration of
2 x 108 platelets/ml. A sample (0.5 ml) is pre-incubated for two minutes at 37°C in a Eaton aggregemeter with stirring, either with vehicle alone, or with vehicle containing the particular compound under test. PAF is added at a sufficient concentration to give a maximum aggregating response in the absence of test compound (10-8 to 10-9 molar), and the platelet aggregation is measured by following the increase in light transmission of the solution. The experiment is repeated in the presence of test compound at a range of concentrations and the concentration of compound required to reduce the response to 50% of its maximum value is recorded as the
IC50 value.
The activity of the compounds of formula (I) is also demonstrated in vivo by their ability to protect mice from the lethal effect of an injection of PAF. A mixture of PAF (50 μg/kg) and DL-propranolol (5 mg/kg) in 0.9% w/v sodium chloride is injected (0.2 ml) via a tail vein into mice. The compounds under test are either injected into the tail vein immediately prior to the PAF/propranolol injection or administered orally by gavage two hours earlier. The compounds are tested at several doses in groups of 5 mice and the dose which reduces mortality to 50% is recorded as the PD50 value.
For therapeutic use the compounds of the formula (I) will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of
administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for exanple, enough salts or glucose to make the solution isotonic with blood.
For admjnistration to man in the curative or prophylactic treatment of allergic bronchial conditions and arthritis, oral dosages of the compounds will generally be in the range of from 2-1000 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 1 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier. Dosages for intravenous
administration would typically be within the range 1 to 10 mg per single dose as required. For the treatment of allergic and bronchial hyper-reactive conditions, inhalation via a nebuliser or aerosol may be the preferred route of drug administration. Dose levels by this route would be within the range 0.1 to 50 mg per single dose as required. In practice the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. Thus in a further aspect the invention provides a
pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.
The invention also includes a compound of the formula (I) or a pharmaceutically acceptable salt thereof, for use in medicine, in particular in the treatment of allergic and
inflammatory conditions in a human being.
The preparation of the compounds of the invention is further illustrated by the following Examples.
EXAMPLE 1
4-[4-(2-Methylimidazo[4,5-c]pyrid-1-yl)bhenyl]-6,7-dihydro- imidazo[1,5,4-ef]-[1,5]-benzodiazepin-6-one
9-Amino-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]- [1,5]benzodiazepin-4-one (0.765g, 2mmol) was suspended in txiethylorthoforinate (10ml, 60mmol) and formic acid (3ml, 8mmol) added to give a clear solution which was stirred at room temperature for two hours and under reflux for one hour.
On cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate such that the aqueous phase had pH8. The organic extract was washed with water, dried over magnesium sulphate and the drying agent filtered off. Pre-adsorption silica (Kieselgel 60, 70-230 mesh, 1g) was added to the filtrate which was concentrated to dryness under reduced pressure. The residue was purified by flash
chromatography (Kieselgel 60, 230-400 mesh) eluting with 5% diethylamine in ethyl acetate.
Product-containing fractions were combined, concentrated under reduced pressure and the residue triturated with methanol to give the title compound (25mg, 3%) . M.Pt. > 300°C. Analysis %:- Found C, 68.37; H, 3.99; N, 20.33
C23H16N6O. 3/4 H2O requires C, 68.05; H, 4.34; N, 20.70
EXAMPLE 2
2-Methyl-4-[4-(2-methylimidazo-[4,5-c]pyrid-l-yl)phenyl]- 6,7-dihydroimidazo[1,5-4-ef][1,51benzodiazepin-6-one
This compound was prepared by the method of Example 1 substituting teiethylorthoacetate and acetic acid for
triethylorthoformate and formic acid respectively, to yield the title compound, (90mg, 26%)
M.Pt. > 300°C
Analysis %;- Found C, 69.37; H, 4.43 ; N, 19.87
C24H18N6O. 1/2 H2O re quires C, 69.38; H, 4.61; N, 20.23 EXAMPLE 3
2-Hydroxy-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]- 6,7-dihydroimidazo[1,5,4-ef][1,5]benzodiazepin-6-one
Trichloromethylchloroformate (0.1g, 0.5mmol) was added to a stirred suspension of 9-amino-4-[4-(2-methylimidazo[4,5-c]- pyrid-1-yl)pheryl][1,5]benzodiazepin-4-one (0.1g, 0.26mmol) in anhydrous 1,2-dichloroethane (5ml) under a nitrogen atmosphere and the reaction mixture stirred under reflux for 16 hours.
Methanol (5ml) was added to give a clear solution, followed by pre-adsorption silica (Kieselgel 60, 70-230 mesh, 1g) and the solution evaporated to dryness under reduced pressure. The residue was purified by flash chromatography (Kieselgel 60, 230-400 mesh) eluting with 25% methanol in ethyl acetate. Product-containing fractions were combined, evaporated to dryness under reduced pressure and the residue triturated with methanol to give the hygroscopic title ccmpound (55mg, 50%). M.Pt. > 300°C
Analysis %:-
Found C, 64.52; H, 3.99; N, 19.3
C23H16N6O2.H2O requires C, 64.78; H, 4.25; N, 19.7
EXAMPLE 4
4-[4-(2-Methylimidazo[4 ,5-c]pyrid-1-yl)phenyl]-7- ethoxycarbonylmethyl-6,7-dihydroimidazo[1, 5 ,4-ef] [1,5]
benzodiazepin-6-one
Sodium hydride (60% dispersion in mineral oil, 60mg, 1.5mmol) was added to a stirred suspension of the title product from
Example 1 (0.51g, 1.3mmol) in anhydrous dimethylformamide (10ml) under nitrogen. After being stirred under reflux for 1 hour, the reaction inixture was cooled to room temperature, whereupon ethyl bromoacetate (0.166ml, 1.5mmol) was added and the solution stirred for an additional 36 hours at room temperature. The dimethylformamide was evaporated off under reduced pressure. The residue was diluted with water, hydrochloric acid (2M) added to give pH1, followed by sodium hydrogen carbonate to give pH8 and product extracted with ethyl acetate. The organic extract was washed three times with water, dried over magnesium sulphate and the drying agent filtered off. Pre-adsorption silica (Kieselgel 60,70-230 mesh, 2g) was added to the filtrate which was evaporated to dryness under reduced pressure.
The residue was purified by flash chromatography (Kieselgel 60, 230-400 mesh) eluting with 2% methanol in chloroform. Product containing fractions were combined, evaporated to dryness under reduced pressure and the residue triturated with ether to give the yellow title compound (30mg, 5%).
M.Pt. 237°-239°C
Analysis%:-
Found C, 66.08; H, 4.65; N, 16.91
C27H22N6O3.3/4 H2O requires C, 65.91; H, 4.81; N, 17.08
EXAMPLE 5
7-Methyl-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-6,7- dihydroimidazo[1,5,4-ef][1,5]benzodiazepin-6-one
The procedure of Example 4 was followed, using methyl iodide instead of ethyl bromoacetate, to yield the title compound, (30mg, 13%). M.Pt. 320°-323°C
Analvsis%:-
Found C, 69.32; H, 4.50; N, 20.25
C24H18N6O. 1/2 H2O requires C, 69.38; H, 4.61; N, 20.23 PRE PARATION
6-Amino-2,3-dihydro-4-[4-(2-methylim idazo[4,5-c]pyrid-1-yl)- phenyl]-1H-[1,5]benzodiazepin-2-one
(a) 2 ,3-Dihydro-4-[4-(2-methylimidazo[4 ,5-c]pyrid-1-yl)phenyl]- 6-nitro-1H-[1,5] benzodiazepin-2-one
A mixture of 3-nitro-1,2-phenylenediamine (5g, 33mmol) and ethyl 4'-(2-methylimidazo[4,5-c]-pyrid-1-yl)benzoylacetate (9.7g, 10mmol) in 100 ml of toluene was heated at reflux for 16 hours. After cooling, the red/orange precipitate (12g) was filtered and washed with ether.
This material was used directly without further purification in Step (b) belcw, m.p. 200°C (broad).
1Ή-NMR (300MHz, DMSO-d6) 2.52 (3H, s), 4.30 (2H, s), 6.68 (1H, s), 7.27 (1H, d, J 5 Hz), 7.82 and 8.29 (each 2H, d, J 8 Hz), 8.33 (1H, d, J 5 Hz), 8.92 (1H, s) and 9.70 (1H brs).
Ethyl 4'-(2-mtethylimidazo[4,5-c]-pyrid-1-yl)benzoylacetate may be prepared as described in European Patent Application No. 0310386A.
(b) A solution of the product from Step (a) (10.3g, 25mmol), and stanncus chloride dihydrate (28g, 125mmol) in 2M HCl (20ml), ethanol (40ml) and water (75ml) was heated at reflux for 20 minutes, then stood at ambient temperature overnight (16 hours). Precipitated solids were filtered off, then the filtrate was adjusted to pH 6 by addition of saturated aqueous sodium bicarbonate and extracted with
dichloromethane. The organic layer was dried (magnesium sulphate) and evaporated to a solid (3g). Two crude batches, obtained as described above, were chromatographed on silica gel, eluting using a gradient of 2-10% of diethylamine in ethyl acetate to afford the title compound as a yellow solid (3.7g, 20%), m.p. 259-263°C.
Analysis %:-
Found C, 67.63; H, 4.86; N, 21.56%
C22H18N60.1/2 H2O requires: C, 67.51; H, 4.89; N, 21.47%

Claims

1. A compound of formula (I):
wherein R1 is H or C1-C2 alkyl optionally substituted by a substituent selected from phenyl, halophenyl, pyridyl, (C1-C4 alkoxy) carbonyl and di-(C1-C4 alkyl) amino, or is C2-C4 alkyl substituted by hydroxyl or by one or two C1-C4 alkoxy groups or is
(CEL) OONR7R8 where n is an integer from 1 to 4 and R7 and R8 are each independently H or C1-C4 alkyl,
R2 is selected from H, CH and C1-C4 alkyl,
R3 is selected from halo and C1-C4 alkyl,
R4 is methyl,
and p is an integer from 0 to 3 and m is an integer from 0 to 3;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, in which R1 is H, CH3 or
ethoxycarbonylmethyl.
3. A compound according to claim 1 or 2, in which R2 is H, CH or
CH3.
4. 7-Methyl-4-[4-(2-methylimidazo[4,5-c]pyrid-1-yl)phenyl]-6, 7- dihydroimidazo[1,5,4-ef] [1,5]benzodiazepin-6-one.
5. 4-[4-(2-Methylimidazo[4,5-c]pyrid-1-yl)phenyl]-7- ethoxycarbonylmethyl-6,7-dihydroimidazo[1,5,4-ef] [1,5] benzodiazepin-6-one.
6. A composition comprising a compound according to any
preceding claim and a pharmaceutical carrier or excipient.
7. A compound according to any one of claims 1 to 5 for use in medicine.
8. Use of a compound according to any one of claims 1 to 5 for making a medicament for antagonising platelet activating factor.
9. A method of making a compound of formula (I) :
wherein R1 is H or C1-C4 alkyl optionally substituted by a substituent selected from phenyl, halophenyl, pyridyl, (C1-C4 alkoxy) carbonyl and di-(C1-C4 alkyl) amino, or is C2-C4 alkyl substituted by hydroxyl or by one or two C1-C4 alkoxy groups or is (CH2) CONR7 R8 where n is an integer from 1 to 4 and R7 and R8 are each independently H or C1-C4 alkyl, R2 is selected from H, CH and C1-C4 alkyl,
R3 is selected from halo and C1-C4 alkyl,
R4 is methyl,
and p is an integer from 0 to 3 and m is an integer from 0 to
3;
or a pharmaceutically acceptable salt thereof which comprises allowing a compound of formula (II):
wherein R3, R4, p and m are as defined for formula (I), to react either with an acid of formula R2CO2H and an orthoester thereof, where R2 is as defined for formula (I), or with tridhloroethyl chloroformate, if necessary allowing the product to react with a compound of formula R1X wherein R1 is an optionally substituted alkyl group as defined for formula (I) and X is Cl, Br or I,
and if necessary forming a salt of the product.
EP91915634A 1990-09-05 1991-09-02 Substituted 6,7-dihydroimidazo(1,5,4-ef)(1,5)benzodiazepin-6-ones, their preparation and pharmaceutical compositions Withdrawn EP0548125A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9019409 1990-09-05
GB909019409A GB9019409D0 (en) 1990-09-05 1990-09-05 Therapeutic agents

Publications (1)

Publication Number Publication Date
EP0548125A1 true EP0548125A1 (en) 1993-06-30

Family

ID=10681724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91915634A Withdrawn EP0548125A1 (en) 1990-09-05 1991-09-02 Substituted 6,7-dihydroimidazo(1,5,4-ef)(1,5)benzodiazepin-6-ones, their preparation and pharmaceutical compositions

Country Status (8)

Country Link
EP (1) EP0548125A1 (en)
JP (1) JPH06500091A (en)
CA (1) CA2091057A1 (en)
FI (1) FI930967A0 (en)
GB (1) GB9019409D0 (en)
IE (1) IE913102A1 (en)
PT (1) PT98851A (en)
WO (1) WO1992004354A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104933A (en) * 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
DK0389189T3 (en) * 1989-03-23 1994-06-20 Pfizer Diazepine anti-allergy agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9204354A1 *

Also Published As

Publication number Publication date
CA2091057A1 (en) 1992-03-06
FI930967A7 (en) 1993-03-04
FI930967L (en) 1993-03-04
WO1992004354A1 (en) 1992-03-19
IE913102A1 (en) 1992-03-11
PT98851A (en) 1992-07-31
JPH06500091A (en) 1994-01-06
FI930967A0 (en) 1993-03-04
GB9019409D0 (en) 1990-10-17

Similar Documents

Publication Publication Date Title
US5250531A (en) Dihydropyrimidine antiallergy agents
US4663326A (en) Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs
US4853392A (en) Fused 1,4-dihydropyridines as antiallergy and antiinflammatory agents
US5248681A (en) Dihydropyridine antiallergy agents
EP0294074B1 (en) Dihydropyridine anti-allergic and anti-inflammatory agents
US4801598A (en) Dihydropyridine anti-allergic and anti-inflammatory agents
JPH01254678A (en) Dihydropyridine compounds
EP0549598A1 (en) 2-METHYLIMIDAZO[4,5-c]PYRIDINE DERIVATIVES AND THERAPEUTIC AGENTS
EP0329357B1 (en) Dihydropyridine anti-allergic and anti-inflammatory agents
EP0548125A1 (en) Substituted 6,7-dihydroimidazo(1,5,4-ef)(1,5)benzodiazepin-6-ones, their preparation and pharmaceutical compositions
US4963560A (en) 1,4-dihydropyridine derivatives
EP0551291A1 (en) Therapeutic (paf antagonists) agents
EP2725025A1 (en) Derivatives of 1H-indole-3-carboxamide and their use as P2Y12 antagonists
EP0462986B1 (en) Imidazopyrimidine antiallergy agents
US5214044A (en) 1,4-dihydropyridines useful as pharmaceuticals
JP3049284B2 (en) Hydantoin derivatives and preventive and therapeutic agents for diabetic complications and cardiovascular diseases using the same as active ingredients
JPH0710877A (en) 4-heteroalicyclic-pyrrolo(2,3-d)pyrimidine
JPH03264585A (en) Imidazoquinolone derivative
JPH04503516A (en) Dihydropyrimidine antiallergic agent
PL165358B1 (en) Method for preparation of the new diazepine derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19930917

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940128

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER INC.

Owner name: PFIZER LIMITED